フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Resolutions at the Annual General Meeting in Medivir on 5 May 2022 PR Newswire HUDDINGE, Sweden, May 5, 2022 HUDDINGE, Sweden, May 5, 2022...
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2022 PR Newswire HUDDINGE, Sweden, April 28, 2022 HUDDINGE, Sweden, April 28, 2022 /PRNewswire/...
Medivir to present at the Redeye Orphan Drugs Conference PR Newswire STOCKHOLM, April 25, 2022 STOCKHOLM, April 25, 2022 /PRNewswire/ -- Medivir...
Medivir to participate at the Kempen Life Sciences Conference PR Newswire STOCKHOLM, Sweden, April 19, 2022 STOCKHOLM, Sweden, April 19, 2022...
Medivir 2021 Annual Report published PR Newswire STOCKHOLM, April 5, 2022 STOCKHOLM, April 5, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm:...
Notice of Annual General Meeting of Medivir AB (publ) PR Newswire HUDDINGE, Sweden, April 4, 2022 HUDDINGE, Sweden, April 4, 2022 /PRNewswire/...
A subgroup analysis of Medivir´s phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA pain PR...
Medivir to present at the Erik Penser Bank Health Care Day PR Newswire STOCKHOLM, Feb. 22, 2022 STOCKHOLM, Feb. 22, 2022 /PRNewswire/ -- Medivir...
MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2021 Significant progress, both in the clinical program and in our business development PR...
Medivir's MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamide PR Newswire STOCKHOLM, Jan. 18, 2022 STOCKHOLM, Jan...
Jens Lindberg takes office as CEO of Medivir on January 24 PR Newswire STOCKHOLM, Jan. 17, 2022 STOCKHOLM, Jan. 17, 2022 /PRNewswire/ -- Medivir...
Medivir to present at the H.C. Wainwright BioConnect Virtual Conference PR Newswire STOCKHOLM, Jan. 10, 2022 STOCKHOLM, Jan. 10, 2022...
First patient dosed in the MIV-818 combination study PR Newswire STOCKHOLM, Dec. 14, 2021 STOCKHOLM, Dec. 14, 2021 /PRNewswire/ -- Medivir AB...
Medivir to present at the Erik Penser Bank Life Science Day PR Newswire STOCKHOLM, Dec. 1, 2021 STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Medivir...
Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published PR...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約